WuXi Healthcare Ventures has returned to support the drug developer's series B round, which included Taikang Insurance.
China-based biopharmaceutical company CStone Pharmaceuticals closed a $260m series B round yesterday featuring insurance provider Taikang and WuXi Healthcare Ventures, the strategic investment arm of pharmaceutical research firm WuXi PharmaTech.
The round, which was led by Singapore’s sovereign wealth fund, GIC, also featured 6 Dimensions Capital, the investment firm formed by WuXi Healthcare Ventures and venture capital firm Frontline BioVentures.
Sequoia Capital China, Yunfeng Capital, Citic PE, Arch Venture Partners, Hillhouse Capital, King Star Capital, 3W Partners, Avict, Terra Magnum…
